Sunday, June 16, 2024

Sharps Technology jumps on $200M sales agreement for syringes with Nephron Pharma

Must read

Medical syringes

Henrik Sorensen/DigitalVision via Getty Images

  • Shares of Sharps Technology (NASDAQ:STSS) surged on Thursday after the company said it signed a 5-year, $200 million syringe sales agreement with Nephron Pharmaceuticals.
  • STSS +33.4% at $0.61 in early open market trading.
  • The agreement would complement the company’s asset purchase agreement to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina.
  • Product delivery is scheduled to begin late in the second quarter of 2025, with projected revenue totaling approximately $37 million for the first 12 months of sales.
  • Press Release.

More articles

Latest article